Bayer Healthcare and ComGenex extend drug discovery collaboration
Bayer Healthcare and Hungarian company ComGenex have renewed their exclusive chemistry collaboration for the sixth consecutive year.
Bayer Healthcare and Hungarian company ComGenex have renewed their exclusive chemistry collaboration for the sixth consecutive year.
During the extended term ComGenex will focus on further improving the overall properties of compound libraries by applying proprietary design criteria and extending chemical diversity. The provided potentially bioactive compound libraries will be used for applications in all discovery research areas of Bayer HealthCare's pharma division.
Based in Budapest, ComGenex is an integrated discovery service provider for the pharmaceutical and biotechnology industries. The company integrates innovative discovery-related technologies including proprietary methods in the area of chemistry, instrumentation, high-throughput analytics, informatics and ADME.
'Our hard work over the years has paid off and we are glad that we were able to build a knowledge base and service portfolio that leading pharmaceutical companies like Bayer can utilise efficiently in their discovery process,' said Dr Laszlo Ürge, ceo of ComGenex.